Pharmacologic treatment of dementia and mild cognitive impairment: Critical appraisal

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Medications approved for the treatment of dementia remain the target of controversy despite data supporting their utility. Critics argue that their cognitive benefits, which are modest at best, are not a sufficient standard of social desirability to outweigh the associated costs and inconvenience. A comprehensive approach combining behavioral and pharmacologic interventions is widely accepted but data to demonstrate the social significance is lacking. As a result, both clinical practice and public expectations have outstripped the evidence base. Uncertainty about meaningful outcomes can be reduced with studies of new interventions. However, more powerful interventions will almost certainly mean more troublesome side effects. Both social consensus and refined measures of outcome will be required to meet the inevitable controversy over definitions of benefit.

Original languageEnglish (US)
Pages (from-to)19-21
Number of pages3
JournalPrimary Psychiatry
Volume12
Issue number7
StatePublished - Jul 2005

Fingerprint

Social Desirability
Uncertainty
Dementia
Consensus
Outcome Assessment (Health Care)
Costs and Cost Analysis
Cognitive Dysfunction

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Genetics

Cite this

Pharmacologic treatment of dementia and mild cognitive impairment : Critical appraisal. / Kennedy, Gary J.

In: Primary Psychiatry, Vol. 12, No. 7, 07.2005, p. 19-21.

Research output: Contribution to journalArticle

@article{b9863bb5f91f450ebd35872032a8dfc4,
title = "Pharmacologic treatment of dementia and mild cognitive impairment: Critical appraisal",
abstract = "Medications approved for the treatment of dementia remain the target of controversy despite data supporting their utility. Critics argue that their cognitive benefits, which are modest at best, are not a sufficient standard of social desirability to outweigh the associated costs and inconvenience. A comprehensive approach combining behavioral and pharmacologic interventions is widely accepted but data to demonstrate the social significance is lacking. As a result, both clinical practice and public expectations have outstripped the evidence base. Uncertainty about meaningful outcomes can be reduced with studies of new interventions. However, more powerful interventions will almost certainly mean more troublesome side effects. Both social consensus and refined measures of outcome will be required to meet the inevitable controversy over definitions of benefit.",
author = "Kennedy, {Gary J.}",
year = "2005",
month = "7",
language = "English (US)",
volume = "12",
pages = "19--21",
journal = "Primary Psychiatry",
issn = "1082-6319",
publisher = "MBL Communications",
number = "7",

}

TY - JOUR

T1 - Pharmacologic treatment of dementia and mild cognitive impairment

T2 - Critical appraisal

AU - Kennedy, Gary J.

PY - 2005/7

Y1 - 2005/7

N2 - Medications approved for the treatment of dementia remain the target of controversy despite data supporting their utility. Critics argue that their cognitive benefits, which are modest at best, are not a sufficient standard of social desirability to outweigh the associated costs and inconvenience. A comprehensive approach combining behavioral and pharmacologic interventions is widely accepted but data to demonstrate the social significance is lacking. As a result, both clinical practice and public expectations have outstripped the evidence base. Uncertainty about meaningful outcomes can be reduced with studies of new interventions. However, more powerful interventions will almost certainly mean more troublesome side effects. Both social consensus and refined measures of outcome will be required to meet the inevitable controversy over definitions of benefit.

AB - Medications approved for the treatment of dementia remain the target of controversy despite data supporting their utility. Critics argue that their cognitive benefits, which are modest at best, are not a sufficient standard of social desirability to outweigh the associated costs and inconvenience. A comprehensive approach combining behavioral and pharmacologic interventions is widely accepted but data to demonstrate the social significance is lacking. As a result, both clinical practice and public expectations have outstripped the evidence base. Uncertainty about meaningful outcomes can be reduced with studies of new interventions. However, more powerful interventions will almost certainly mean more troublesome side effects. Both social consensus and refined measures of outcome will be required to meet the inevitable controversy over definitions of benefit.

UR - http://www.scopus.com/inward/record.url?scp=22544449236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22544449236&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:22544449236

VL - 12

SP - 19

EP - 21

JO - Primary Psychiatry

JF - Primary Psychiatry

SN - 1082-6319

IS - 7

ER -